https://pubmed.ncbi.nlm.nih.gov/38369891/ hepatitis C

J Pediatr Gastroenterol Nutr. 2024 Feb 18.

doi: 10.1002/jpn3.12160. Online ahead of print.

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings

Giuseppe Indolfi 1 2, Regino P Gonzalez-Peralta 3, Maureen M Jonas 4, Manal Hamdy-El Sayed 5, Björn Fischler 6, Etienne Sokal 7, Stefan Wirth 8, Emanuele Nicastro 9; Hepatology Committee of the ESPGHAN

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV-related liver disease has advanced considerably thanks to development and improvements in therapy. Direct-acting antiviral regimens are safe and effective. Three regimens with pangenotypic activity (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir) and three regimens with genotype-specific activity (sofosbuvir/ribavirin, sofosbuvir/ledipasvir and elbasvir/grazoprevir) have been approved with age-specific limitation for treatment of children with chronic hepatitis C by the European Medicines Agency and the United States Food and Drug Administration. The World Health Organization has set the ambitious target to eliminate hepatitis C as a major public health threat by 2030 and based its actions against HCV on the large use of direct acting antivirals. These updated European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommendations on treatment of hepatitis C describe the optimal therapeutic management of adolescents and children with HCV infection including specific indications for those living in resource-limited settings.